Automated cryopreservation process development for leukapheresis to support supply chains

Watch the video or read the poster for insights into: achieving increased consistency for starting material in cell and gene therapy with repeatability using a process that can easily scale-up; leveraging Quality by Design (QbD) development of an advanced cryoprocess for processing fresh leukapheresis; mitigating risk via increased sterility & decreased variability by using an automated closed system; and attaining cryopreservation of leukapheresis material within 24 hours of collection across the United States and Europe. Alexandre Michaux has a Master’s Degree in Molecular and Cellular Biology from the University of Namur, Belgium. He performed his PhD thesis at the Ludwig Institute for Cancer Research, Brussels, and went on to work at Celyad Oncology as a Senior Scientist, R&D. Following this, he joined Cryoport Systems as Manager, Process Development and MSAT where his current focus is on the IntegriCell™ platform to support cryo-process development for advanced cell and gene therapies.